←
Andre Esteva, PhD844 posts
Andre Esteva, PhD avatar

Andre Esteva, PhD

@AndreEsteva

Co-Founder & CEO, Artera. Previously: Head of Medical AI, Salesforce | Stanford AI | Google Research

◷ Joined May 2013▧ 81 Photos and videos
Nathan Silberman avatar
⟳ Andre Esteva, PhD retweeted
Nathan Silberman@NCSilberman·4 Dec 2024

Are open source pathology models ready for the clinic? Despite significant progress - not quite yet! These models show increased accuracy on retrospective datasets but struggle to deal with real-world variation as outlined on the @arteraAI tech blog: arteraai.medium.com/are-open…

Elon Musk avatar
⟳ Andre Esteva, PhD retweeted
Elon Musk@elonmusk·4 Dec 2024

Absolutely true

🇺🇸 STEVE JOBS: THE BEST MANAGERS ARE GREAT CONTRIBUTORS... WHO NEVER WANTED TO BE MANAGERS "At Apple, we thought hiring professional managers would make us a big company. It didn’t work—most were bozos who could manage but couldn’t do anything else. The best managers? Great individual contributors who never wanted the job but took it because they knew no one else could do it as well." Source: BusinessX on IG

0:34
Andre Esteva, PhD avatar
Andre Esteva, PhD@AndreEsteva·2 Sep 2024

TSA + CLEAR is somehow slower than TSA alone. Baffling. Paying extra to go slower is the opposite of product market fit. 🧐

Andre Esteva, PhD avatar
Andre Esteva, PhD@AndreEsteva·6 Aug 2024

The @arteraAI Prostate Cancer Test can now inform active surveillance treatment decisions for low-risk patients. To propel adoption, we've integrated with @PathNetLab - a fully digital pathology lab that serves about 10% of the annual US prostate cancer volume across 200+ clinics in 27 states. Our test report will now be delivered with immediate turnaround time to clinicians - at the same time as the diagnostic pathology report. This is in addition to being the only predictive test in the @NCCN guidelines, and being reimbursed by @MedicareGov . About 40% of localized prostate cancer patients are NCCN low-risk. In these patients the key clinical decision that needs to be made is whether to put them on active surveillance or active treatment. And if you don't need treatment, you certainly don't want to be placed on it. Artera's test has been updated to help inform clinicians and patients whether they would benefit from active treatment vs surveillance. It is a privilege to work with @PathNetLab and its founder Adam Cole to support prostate cancer patients at scale. Interested clinicians can order our test at artera.ai #prostatecancer #digitalpathology #arteraai #biomarkers #AI #machinelearning #biomarkers #medicalAI businesswire.com/news/home/2…

Andre Esteva, PhD avatar
Andre Esteva, PhD@AndreEsteva·4 Mar 2024

Moreover, it was included based on a Category 2A recommendation, signifying uniform consensus amongst the NCCN expert panel that our test is appropriate for prostate cancer patients.

Andre Esteva, PhD avatar
Andre Esteva, PhD@AndreEsteva·4 Mar 2024

It has the highest number of clinical endpoints of any test (distant metastasis, biochemical recurrence, prostate cancer-specific mortality), and it is only one of two tests with level 1B evidence, according to the Simon Criteria.

Andre Esteva, PhD avatar
Andre Esteva, PhD@AndreEsteva·4 Mar 2024

There are only four companies listed in guidelines for prostate cancer. Artera's test is the only one recommended as predictive of therapy benefit.

Andre Esteva, PhD avatar
Andre Esteva, PhD@AndreEsteva·1 Feb 2024

The infusion of this additional funding is a crucial catalyst, propelling ArteraAI forward in its mission to personalize cancer therapy through AI-enabled predictive and prognostic tests. We are committed to ushering in the era of democratized precision medicine.